Skip to main content
Year archive

Evotec SE — 2023 filings

All 82 regulatory filings released by Evotec SE (EVT) in 2023, sourced directly from the official regulator.

82 Filings
2023 Period
2023 filings (82)
Filing Released Lang
Evotec SE: Dr. Werner Lanthaler, sell
Director's Dealing
2023-12-28 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, sell
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec SE: Dr. Werner Lanthaler, buy
Director's Dealing
2023-12-22 English
Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
Regulatory Filings
2023-12-19 English
Evotec enters partnership with Charite to expand molecular patient database in autoimmune diseases
Environmental & Social Information
2023-12-14 English
Evotec-partner Jingxin receives approval for EVT201 in China
Regulatory Filings
2023-12-06 English
Declaration of Compliance with the German Corporate Governance Code for the year 2023
Governance Information
2023-12-01 English
Entsprechenserklärung zum Deutschen Corporate Governance Kodex für das Jahr 2023
Governance Information
2023-12-01 German
Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
Regulatory Filings
2023-11-15 English
Evotec SE reports results for the first nine months 2023 and provides corporate update
Earnings Release 9M 2023
2023-11-08 English
Präsentation Q3 2023
Investor Presentation FY 2023
2023-11-08 English
Q3 statement / Q3 financial report 2023
Interim / Quarterly Report 9M 2023
2023-11-08 German
Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
Regulatory Filings
2023-11-07 English
Evotec SE to announce results for the first nine months 2023 on 08 November 2023
Report Publication Announcement
2023-11-01 English
Company Presentation November 2023 (English)
Investor Presentation
2023-11-01 English
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
Regulatory Filings
2023-10-05 English
Company Presentation October 2023 (English)
Investor Presentation
2023-10-01 German
Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
Regulatory Filings
2023-09-27 English
Evotec and Novo Nordisk launch LAB eN2 to accelerate translation in cardiometabolic diseases
Environmental & Social Information
2023-09-26 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-09-25 English
Half-yearly financial report 2023
Interim / Quarterly Report H2 2023
2023-08-31 English
Evotec SE reports results for the first half-year 2023 and provides corporate updates
Earnings Release H1 2023
2023-08-29 English
Präsentation H1 2023
Investor Presentation
2023-08-29 English
Evotec SE reports first half-year 2023 results on 29 August 2023
Report Publication Announcement
2023-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-08-01 English
Evotec provides update on financial impact of cyber-attack
Earnings Release H1 2023
2023-07-27 English
Evotec provides update on financial impact of cyber-attack
Earnings Release FY 2023
2023-07-27 English
Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
M&A Activity
2023-07-11 English
Just Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
Regulatory Filings
2023-07-05 English
Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
Regulatory Filings
2023-06-29 English
Report Publication Announcement 2023
Report Publication Announcement
2023-06-26 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-06-21 English
Evotec SE Annual General Meeting 2023 approves all proposed agenda items
AGM Information
2023-06-20 English
Vergütungsbericht 2022 der Evotec SE
Remuneration Information
2023-06-20 German
Remuneration Report 2022 of Evotec SE
Remuneration Information
2023-06-20 English
Präsentation des Vorstands Hauptversammlung 2023
AGM Information
2023-06-20 German
Evotec presents sustainability strategy
Environmental & Social Information
2023-06-05 English
Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
Regulatory Filings
2023-06-02 English
Annual financial report 2022 (PDF)
Annual Report FY 2022
2023-05-16 English
Evotec SE: Bekanntmachung der Einberufung zur Hauptversammlung am 20.06.2023 in Hamburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2023-05-15 German
Jahresfinanzbericht 2022 (PDF)
Annual Report FY 2022
2023-05-15 German
Q1 statement / Q1 financial report 2023
Interim / Quarterly Report Q1 2023
2023-05-15 English
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
Report Publication Announcement
2023-05-12 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-11 English
Report Publication Announcement 2023
Report Publication Announcement
2023-05-11 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-11 English
Just Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
Regulatory Filings
2023-05-09 English
Just Evotec Biologics enters strategic biosimilars partnership with Sandoz
Regulatory Filings
2023-05-09 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-05 English
Report Publication Announcement 2023
Report Publication Announcement
2023-05-02 English
Report Publication Announcement 2023
Report Publication Announcement
2023-05-02 English
Declaration of Corporate Management 2022
Governance Information
2023-04-24 English
Erklärung zur Unternehmensführung 2022
Governance Information
2023-04-24 German
Evotec SE provides update on cyber attack
Regulatory Filings
2023-04-10 English
Cyber Attack on Evotec
Legal Proceedings Report
2023-04-07 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-04-05 English
Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
Regulatory Filings
2023-03-28 English
Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
M&A Activity
2023-03-28 English
Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' very strong performance in a challenging year
Earnings Release FY 2022
2023-03-28 English
Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
Regulatory Filings
2023-03-24 English
Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
Report Publication Announcement
2023-03-21 English
Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
Regulatory Filings
2023-03-16 English
Evotec receives 150 m loan from European Investment Bank
Capital/Financing Update
2023-02-10 English
Evotec and Related Sciences expand integrated drug discovery and development partnership
Regulatory Filings
2023-02-09 English
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
Board/Management Information
2023-02-07 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2023-01-31 English
Evotec announces agreement with Janssen to develop immune-based therapies
Regulatory Filings
2023-01-26 English
Evotec SE: Dr. Craig Johnstone, Purchase of shares by exercising stock options (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Dr. Craig Johnstone, Exercise against cash settlement (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Dr. Cord Dohrmann, Purchase of shares by exercising stock options (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Dr. Cord Dohrmann, Exercise against cash settlement (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Enno Spillner, Purchase of shares by exercising stock options (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Enno Spillner, Exercise against cash settlement (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Dr. Werner Lanthaler, Purchase of shares by exercising stock options (Share Performance Plan)
Director's Dealing
2023-01-20 English
Evotec SE: Dr. Werner Lanthaler, Exercise against cash settlement (Share Performance Plan)
Director's Dealing
2023-01-20 English